SG/CALL/ELI LILLY & CO/460/0.1/17.01.25 | Delayed Deutsche Boerse AG 06:14:13 2024-07-01 EDT | ||
| 43.08 EUR | -0.12% |
|
| Current month | +25.93% | ||
| 1 month | +29.60% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 24-07-01 | 43.08 | -0.12% |
| 24-06-28 | 43.13 | +0.65% |
| 24-06-27 | 42.85 | +0.56% |
| 24-06-26 | 42.61 | +0.19% |
| 24-06-25 | 42.53 | +2.14% |
Delayed Quote Deutsche Boerse AG
Last update July 01, 2024 at 06:14 am
More quotesStatic data
| Product type | Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | 
Société Générale
|
| WKN | SV290X |
| ISIN | DE000SV290X3 |
| Date issued | 2023-04-12 |
| Strike | 460 $ |
| Maturity | 2025-01-17 (201 Days) |
| Parity | 10 : 1 |
| Emission price | 3.28 € |
| Emission volume | N/A |
| Settlement | règlement en espèces |
| Currency | EUR |
Technical Indicators
| Highest since issue | 43.8 € |
|---|---|
| Lowest since issue | 3.05 € |
| Delta | 0x |
| Omega | 0.000000 |
| Premium | 0x |
| Gearing | 0x |
| Moneyness | 1.968 |
| Difference Strike | -445.4 $ |
| Difference Strike % | -96.82% |
| Intrinsic value | 41.43 |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
905.4
USD
Average target price
868.9
USD
Spread / Average Target
-4.03%
- Stock Market
- Warrants
- Warrant
